USFDA issues no observation on Zydus Ahmedabad facility
New Delhi: Zydus Cadila’s wholly-owned subsidiary Alidac Pharmaceuticals has not received any observation from the US health regulator after the closure of inspection of its manufacturing facility located at SEZ, Ahmedabad.
“The US Food and Drug Administration (USFDA) inspected the manufacturing facility of our wholly-owned subsidiary, Alidac Pharmaceuticals Ltd, located at SEZ, Ahmedabad from May 28 to June 5, 2018. At the end of the inspection, no observation (483) is issued,” the company said in a BSE filing.
The site manufactures oncology injectables for the regulated markets, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd